(redirected from Butyrylcholinesterase)
Also found in: Dictionary, Medical.
BChEBachelor of Chemical Engineering
BCHEBrevard Christian Home Educators (Florida)
BCHEBath College of Higher Education (Bath Spa University; England, UK)
BCHEBig Country Home Educators (Abilene, TX)
References in periodicals archive ?
Butyrylcholinesterase is a glycoprotein enzyme found in plasma and in various compartments within the body and is widely distributed in the nervous system.
who demonstrated that low butyrylcholinesterase activities were associated with higher allcause and cardiovascular mortality in individuals whose coronary artery status was unknown.
L-lactate reduces in vitro the inhibition of butyrylcholinesterase (BChE) by paraoxon (E 600).
Currently used FDA approved drugs for the treatment of Alzheimer disease Starting Dosing Drug Unique characteristics dose schedule Cholinesterase inhibitors Donepezil Acetylcholinesterase specificity 5 mg Once daily Rivastigmine Butyrylcholinesterase specificity 1.
In an earlier study, MMSE scores in patients treated with rivastigmine, an inhibitor of butyrylcholinesterase (BuChE) as well as AChE, appeared to decline more slowly than predicted, over a period of up to 5 years.
Exelon(x) is unique in that it inhibits two enzymes -- acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) which normally decrease the levels of acetylcholine in the brain.
has found that a novel form of the enzyme butyrylcholinesterase (BChE), when elevated in the brain, is a diagnostic marker specific for AD because its increase has not been seen in other neurological disorders.
Aricept (donepezil) inhibits acetylcholinesterase only; Cognex (tacrine) also inhibits butyrylcholinesterase but is no longer prescribed because it causes liver toxicity, said Dr.
The compound selectively inhibits butyrylcholinesterase (BChE), an enzyme that degrades the neurotransmitter acetylcholine and predominates in the advanced AD brain.
The present study investigated acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities of G.
Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the Company's recombinant butyrylcholinesterase (rBChE) bioscavenger demonstrating that it successfully targets and binds to a broad spectrum of nerve agents, including sarin and tabun, which are believed to be part of the Syrian chemical weapons inventory.
Butyrylcholinesterase (BChE),4 also known as pseudocholinesterase, is distributed in the white matter of the central nervous system and in the blood.